1021 related articles for article (PubMed ID: 18408761)
1. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Li D; Ambrogio L; Shimamura T; Kubo S; Takahashi M; Chirieac LR; Padera RF; Shapiro GI; Baum A; Himmelsbach F; Rettig WJ; Meyerson M; Solca F; Greulich H; Wong KK
Oncogene; 2008 Aug; 27(34):4702-11. PubMed ID: 18408761
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Modjtahedi H; Cho BC; Michel MC; Solca F
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jun; 387(6):505-21. PubMed ID: 24643470
[TBL] [Abstract][Full Text] [Related]
3. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Singh SS; Mattheolabakis G; Gu X; Withers S; Dahal A; Jois S
Eur J Med Chem; 2021 Apr; 216():113312. PubMed ID: 33667849
[TBL] [Abstract][Full Text] [Related]
4. TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
Oguchi K; Araki H; Tsuji S; Nakamura M; Miura A; Funabashi K; Osada A; Tanaka S; Suzuki T; Kobayashi SS; Mizuarai S
Cancer Sci; 2023 Feb; 114(2):654-664. PubMed ID: 36282234
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Jang J; Son J; Park E; Kosaka T; Saxon JA; De Clercq DJH; Choi HG; Tanizaki J; Eck MJ; Jänne PA; Gray NS
Angew Chem Int Ed Engl; 2018 Sep; 57(36):11629-11633. PubMed ID: 29978938
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel 5,6-Dihydro-4
Yang L; Li Y; Du Y; Guo Y; Guo Z; Liu B; Liu J; Liu Y; Niu H; Sun Y; Yan H; Yang Y; Yu S; Zhang Y; Zhang Y; Zheng K; Zheng N; Zhang X; Zhang Q; Hu L
J Med Chem; 2024 Apr; 67(7):5662-5682. PubMed ID: 38518121
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Kiguchi K; Kitamura T; Moore T; Rumi M; Chang HC; Treece D; Ruffino L; Connolly K; DiGiovanni J
Cancer Prev Res (Phila); 2010 Aug; 3(8):940-52. PubMed ID: 20682802
[TBL] [Abstract][Full Text] [Related]
8. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo.
Guan SS; Chang J; Cheng CC; Luo TY; Ho AS; Wang CC; Wu CT; Liu SH
Oncotarget; 2014 Jul; 5(13):4868-80. PubMed ID: 24947902
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
[TBL] [Abstract][Full Text] [Related]
10. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
Bozzi F; Manenti G; Conca E; Stacchiotti S; Messina A; Dagrada G; Gronchi A; Panizza P; Pierotti MA; Tamborini E; Pilotti S
Neuro Oncol; 2014 Jan; 16(1):72-80. PubMed ID: 24366975
[TBL] [Abstract][Full Text] [Related]
11. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
[TBL] [Abstract][Full Text] [Related]
12. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV; Yang JC; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater SL; Orlov S; Tsai CM; Boyer M; Su WC; Bennouna J; Kato T; Gorbunova V; Lee KH; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M
J Clin Oncol; 2013 Sep; 31(27):3327-34. PubMed ID: 23816960
[TBL] [Abstract][Full Text] [Related]
13. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
14. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Yasuda H; Kobayashi S; Costa DB
Lancet Oncol; 2012 Jan; 13(1):e23-31. PubMed ID: 21764376
[TBL] [Abstract][Full Text] [Related]
15. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
[TBL] [Abstract][Full Text] [Related]
16. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Miller VA; Hirsh V; Cadranel J; Chen YM; Park K; Kim SW; Zhou C; Su WC; Wang M; Sun Y; Heo DS; Crino L; Tan EH; Chao TY; Shahidi M; Cong XJ; Lorence RM; Yang JC
Lancet Oncol; 2012 May; 13(5):528-38. PubMed ID: 22452896
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS; Wu YL; Thongprasert S; Yang CH; Chu DT; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; Yang JJ; Chewaskulyong B; Jiang H; Duffield EL; Watkins CL; Armour AA; Fukuoka M
N Engl J Med; 2009 Sep; 361(10):947-57. PubMed ID: 19692680
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
